HRT Financial’s NervGen Pharma NGEN Stock Holding History

HRT Financial’s Portfolio NGEN Stock Details NGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$90K	Buy	43,858 +22,492	+105%	+$69.8K	﹤0.01%	3644
2026 Q1	$80K	Buy	+21,366	New	+$92.6K	﹤0.01%	3391

Other funds holding NGEN

Empery Asset Management New York $86.5M AUM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Ghisallo Capital Management Boston, Massachusetts $5.1B AUM 39.13% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

HRT Financial's NGEN Position: Q2 2026 in Review

HRT Financial increased its NervGen Pharma (NGEN) stake by 105% in Q2 2026, buying an estimated $69.8K and bringing the position to 43,858 shares worth $90K. The position accounts for ﹤0.01% of the portfolio, ranked #3644.

HRT Financial first reported a position in NGEN in Q1 2026 and has held it in 2 quarters since. 62 funds tracked by Wall St. Rank hold NGEN as of Q2 2026.

HRT Financial held 43,858 shares of NervGen Pharma worth $90K as of Q2 2026.
HRT Financial bought 22,492 NervGen Pharma shares in Q2 2026, an estimated $69.8K.
NervGen Pharma made up ﹤0.01% of HRT Financial's portfolio in Q2 2026, its #3644 holding.
HRT Financial first reported a position in NervGen Pharma in Q1 2026 and has held it in 2 quarters since.
62 funds tracked by Wall St. Rank held NervGen Pharma as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.